Newsroom
Strive to Deliver Breakthroughs
-
February 14, 2025
Harbour BioMed Announces Business Progress and Update
Cambridge, MA, Rotterdam, NL, Shanghai, CN – February 13, 2025 Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceu...
View more -
February 05, 2025
Harbour BioMed Receives NMPA IND Clearance for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease
Cambridge, MA, Rotterdam, NL, Shanghai, CN — February 4, 2025 Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceuti...
View more -
January 10, 2025
Harbour BioMed Announces License Agreement with Windward Bio for HBM9378/SKB378, an Anti-TSLP Fully Human Antibody for Immunological Diseases
Cambridge, MA, Rotterdam, NL, Shanghai, CN — January 10, 2025 Harbour BioMed (HKEX: 02142, the “Company”), a global biophar...
View more -
November 15, 2024
Harbour BioMed Appoints Dr. Raymond Zheng as Chief Business Officer
Cambridge, MA, Rotterdam, NL, Suzhou, CN — November 14, 2024 Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceuti...
View more -
November 08, 2024
Harbour BioMed Announces Submission of IND Application for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease
Cambridge, MA, Rotterdam, NL, Suzhou, CN – November 8, 2024 Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutic...
View more -
October 10, 2024
Harbour BioMed Announces Publication of the Phase I Study Results for Porustobart in Combination with Toripalimab in Advanced Melanoma and Other Solid Tumors
Cambridge, MA, Rotterdam, NL, Suzhou, CN — October 9, 2024 Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical...
View more -
September 14, 2024
Harbour BioMed Announces the Latest Clinical Data on the First-in-Class Fully Human Anti-B7H7/HHLA2 Monoclonal Antibody HBM1020 at the ESMO Congress 2024
Cambridge, MA, Rotterdam, NL, Suzhou, CN — September 14, 2024 Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceuti...
View more -
August 28, 2024
Harbour BioMed Announces 2024 Interim Results
Harbour BioMed (“HBM”, or the "Company”; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and c...
View more -
July 26, 2024
Harbour BioMed to Present the Latest Progress of the First-in-Class Fully Human Anti-B7H7/HHLA2 Monoclonal Antibody HBM1020 at the ESMO Congress 2024
Cambridge, MA, Rotterdam, NL, Suzhou, CN — July 25, 2024 Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutical ...
View more -
July 19, 2024
Harbour BioMed Announces Positive Profit Alert for 2024 Interim Results
Cambridge, MA, Rotterdam, NL, Suzhou, CN – July 19, 2024 Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutical ...
View more
Copyright © 2025 Harbour BioMed. All Rights Reserved
沪公网安备31011502401396号
沪ICP备19015946号-1